science
DME red flag in Merck Brunello phase III? Surrozen finishes rich
Merck & Co. Inc.’s positive top-line data from the pivotal phase IIb/III Brunello trial with remigromig in adults with diabetic macular edema (DME) came with a possible safety downside, but backers of competitor Surrozen Inc. proved happy about the latest news.
ONLY AVAILABLE IN PAID PLANS
Read Full ArticleShare this story
Up next
Related Stories
Practitioner-researchers in social care and social work – hope for the future or promises unfulfilled?
Lse Blogs | Expert Analysis From Lse, The World-le
AMRC Rotor Spin Tester
University Of Sheffield
Young minds develop ideas to tackle climate change
The Bbc
Exploring efficiency and durability in fuel cell catalysts
Physicsworld
NASA's Low-Earth Orbit Economy Faces Crisis as SpaceX Moves Beyond Crew Dragon: Here's Why
Techtimes